Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01177241
NCT01177241CompletedNot Applicable

Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids

NEMA Research, Inc.0 sites10,000 target enrollmentStarted: September 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10,000
Study OverviewStudy DesignEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Using a retrospective analysis of a large commercial claims database and a Medicare database, the investigators evaluated DDEs that have the potential to cause DDIs among chronic low back pain (cLBP) patients on long-term opioid analgesia, which metabolizes through the CYP450 enzyme system, concomitant with other CYP450-metabolized drug(s)

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •chronic low back pain

Exclusion Criteria

  • •pregnancy

Investigators

Sponsor Class
Industry
Responsible Party
Principal Investigator
Principal Investigator

Joseph Pergolizzi, MD

Principal Investigator

NEMA Research, Inc.

Similar Trials

Completed
Not Applicable
Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple PrescriptionsChronic Low Back Pain
NCT01177254NEMA Research, Inc.10,000
Completed
Not Applicable
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions(DDI) Among Osteoarthritis PatientsOsteoarthritis
NCT01177267NEMA Research, Inc.10,000
Completed
Not Applicable
Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic OutcomesChronic Low Back Pain
NCT01177280NEMA Research, Inc.10,000
Completed
Phase 1
A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult ParticipantsHealthy
NCT04410094Janssen Research & Development, LLC32
Completed
Phase 4
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazolePoor Metabolizer Due to Cytochrome P450 CYP2C9 VariantPoor Metabolizer Due to Cytochrome p450 CYP2C19 Variant
NCT03092193University of Sao Paulo8